Drugs / REGN9533
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06665828 | Mar 2025 → Jan 2026 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN9533 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06665828 ↗ |
| Modality | Monoclonal antibody | “a Monoclonal Antibody Against Factor XII” NCT06665828 ↗ |